MULTISCREEN™ STABLE CELL LINES
HUMAN RECOMBINANT CX3CR1 RECEPTOR
1 vial (2 x 106) frozen cells
Sigma Freezing Medium (C-6164)
Expression vector containing full-length human CX3CR1 cDNA (GenBank Accession Number NM_001337) with FLAG tag sequence at N-terminus
Liquid nitrogen upon receiving
Propagation Medium: DMEM, 10% FBS, 1 μg/mL puromycin
Stable in culture for minimum of two months
Background: CX3CR1, (CX3C-chemokine receptor 1, fractalkine receptor or GPR13) is a receptor for the CX3C chemokine fractalkine. CX3CR1 is expressed in cytotoxic effector lymphocytes, including natural killer cells, cytotoxic T lymphocytes and macrophages. Soluble fractalkine causes migration of these cells, whereas the membrane-bound form captures and enhances the subsequent migration in response to secondary stimulation with other chemokines. Furthermore, stimulation through membrane-bound fractalkine activates natural killer cells, leading to increased cytotoxicity and interferon-gamma production. Fractalkine is involved in the pathogenesis of various clinical disease states or processes, such as atherosclerosis, glomerulonephritis, cardiac allograft rejection and rheumatoid arthritis. In addition, polymorphisms in CX3CR1, which reduce its binding activity to fractalkine, have been reported to increase the risk of HIV disease and to reduce the risk of coronary artery disease.
Application: Functional assays
Figure 1. Dose-dependent stimulation of calcium flux upon treatment with ligand, measured with MultiscreenTM Calcium 1.0 No Wash Assay Kit (Multispan MSCA01). Cells were transiently transfected with Gαqi5. Figure 2. Receptor expression on cell surface measured by flow cytometry (FACS) using an anti-FLAG antibody. Thin line: parental cells; thick line: receptor-expressing cells.
Imai et al. (1997) Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91:521-530.
Garin et al. (2003) Two novel fully functional isoforms of CX3CR1 are potent HIV coreceptors. J Immunol 171:5305-5312.